Literature DB >> 21591862

Predictability of vitreous detachment following intravitreal plasmin injection in diabetic macular edema associated with vitreomacular traction.

Amal M Elbendary1, Mohamed M Elwan, Hanan A Azzam, Doaa R Eldeeb.   

Abstract

PURPOSE: To assess preoperative factors associated with postoperative posterior vitreous detachment (PVD) following intravitreal autologous plasmin injection in diabetic macular edema associated with vitreomacular traction.
METHODS: Twenty-five eyes with diabetic macular edema associated with vitreomacular traction as documented with optical coherence tomography were included. Approximately 0.2 IU/0.2 ml of autologous plasmin was injected intravitreally. Condition of the posterior vitreous face (degree of detachment, thickness, reflectivity, and diameter of attached vitreous base) was evaluated preoperatively and postoperatively up to 3 months.
RESULTS: PVD was achieved in ten eyes (41.7%). There was a significant difference (P = 0.03) in mean posterior vitreous face thickness between the eyes with PVD and the eyes with failed PVD. There was a significant correlation between PVD and both posterior vitreous face thickness (P < 0.03%) and degree of posterior vitreous face reflectivity (P = 0.002).
CONCLUSION: In diabetic eyes with vitreomacular traction, the prediction of PVD after plasmin injection is governed by the condition of posterior vitreous face; mainly posterior vitreous face thickness and reflectivity. Eyes with thinner, less reflective posterior vitreous face are more likely to develop PVD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21591862     DOI: 10.3109/02713683.2011.569868

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  6 in total

1.  The design and validation of an optical coherence tomography-based classification system for focal vitreomacular traction.

Authors:  D H W Steel; L Downey; K Greiner; H Heimann; T L Jackson; Z Koshy; D A H Laidlaw; L Wickham; Y Yang
Journal:  Eye (Lond)       Date:  2016-01-15       Impact factor: 3.775

2.  [Pharmacological vitreolysis].

Authors:  C Haritoglou; A Kampik
Journal:  Ophthalmologe       Date:  2013-10       Impact factor: 1.059

3.  Vitreomacular traction syndrome: the role of intravitreal plasmin injection is still not clear.

Authors:  A Grzybowski; F J Ascaso
Journal:  Eye (Lond)       Date:  2013-04-12       Impact factor: 3.775

4.  Ocriplasmin - variable efficacy?

Authors:  David H W Steel; David Wong
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-04       Impact factor: 3.117

Review 5.  Ocriplasmin for symptomatic vitreomacular adhesion.

Authors:  James E Neffendorf; Varo Kirthi; Edward Pringle; Timothy L Jackson
Journal:  Cochrane Database Syst Rev       Date:  2017-10-17

6.  High-level expression, purification, and enzymatic characterization of truncated human plasminogen (Lys531-Asn791) in the methylotrophic yeast Pichia pastoris.

Authors:  Rongzeng Liu; Bing Zhao; Yanling Zhang; Junxiang Gu; Mingrong Yu; Houyan Song; Min Yu; Wei Mo
Journal:  BMC Biotechnol       Date:  2015-06-09       Impact factor: 2.563

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.